82 related articles for article (PubMed ID: 21461891)
1. Lack of food effect on single-dose pharmacokinetics of brivanib, and safety and efficacy following multiple doses in subjects with advanced or metastatic solid tumors.
LoRusso P; Shapiro GI; Hurwitz H; Pilat MJ; Chemidlin J; Kollia G; Syed S; Fischer B; Masson E
Cancer Chemother Pharmacol; 2011 Dec; 68(6):1377-85. PubMed ID: 21461891
[TBL] [Abstract][Full Text] [Related]
2. The effects of liver impairment on the pharmacokinetics of brivanib, a dual inhibitor of fibroblast growth factor receptor and vascular endothelial growth factor receptor tyrosine kinases.
El-Khoueiry A; Posey JA; Castillo Ferrando JR; Krishnamurthi SS; Syed S; Kollia G; Walters I; Fischer BS; Masson E
Cancer Chemother Pharmacol; 2013 Jul; 72(1):53-64. PubMed ID: 23719718
[TBL] [Abstract][Full Text] [Related]
3. Metabolism, excretion, and pharmacokinetics of oral brivanib in patients with advanced or metastatic solid tumors.
Mekhail T; Masson E; Fischer BS; Gong J; Iyer R; Gan J; Pursley J; Patricia D; Williams D; Ganapathi R
Drug Metab Dispos; 2010 Nov; 38(11):1962-6. PubMed ID: 20671097
[TBL] [Abstract][Full Text] [Related]
4. Lack of effect of brivanib on the pharmacokinetics of midazolam, a CYP3A4 substrate, administered intravenously and orally in healthy participants.
Syed S; Clemens PL; Lathers D; Kollia G; Dhar A; Walters I; Masson E
J Clin Pharmacol; 2012 Jun; 52(6):914-21. PubMed ID: 21659627
[TBL] [Abstract][Full Text] [Related]
5. Preclinical pharmacokinetics and in vitro metabolism of brivanib (BMS-540215), a potent VEGFR2 inhibitor and its alanine ester prodrug brivanib alaninate.
Marathe PH; Kamath AV; Zhang Y; D'Arienzo C; Bhide R; Fargnoli J
Cancer Chemother Pharmacol; 2009 Dec; 65(1):55-66. PubMed ID: 19396600
[TBL] [Abstract][Full Text] [Related]
6. A phase I study to determine the safety, pharmacokinetics and pharmacodynamics of a dual VEGFR and FGFR inhibitor, brivanib, in patients with advanced or metastatic solid tumors.
Jonker DJ; Rosen LS; Sawyer MB; de Braud F; Wilding G; Sweeney CJ; Jayson GC; McArthur GA; Rustin G; Goss G; Kantor J; Velasquez L; Syed S; Mokliatchouk O; Feltquate DM; Kollia G; Nuyten DSA; Galbraith S
Ann Oncol; 2011 Jun; 22(6):1413-1419. PubMed ID: 21131369
[TBL] [Abstract][Full Text] [Related]
7. Metabolism and disposition of [14C]brivanib alaninate after oral administration to rats, monkeys, and humans.
Gong J; Gan J; Caceres-Cortes J; Christopher LJ; Arora V; Masson E; Williams D; Pursley J; Allentoff A; Lago M; Tran SB; Iyer RA
Drug Metab Dispos; 2011 May; 39(5):891-903. PubMed ID: 21289073
[TBL] [Abstract][Full Text] [Related]
8. Metabolic chiral inversion of brivanib and its relevance to safety and pharmacology.
Gong J; Gan J; Masson E; Syed S; Xia YQ; Williams D; Pursley J; Jemal M; Humphreys WG; Iyer RA
Drug Metab Dispos; 2012 Dec; 40(12):2374-80. PubMed ID: 22983304
[TBL] [Abstract][Full Text] [Related]
9. Phase I dose-escalation study to determine the safety, pharmacokinetics and pharmacodynamics of brivanib alaninate in combination with full-dose cetuximab in patients with advanced gastrointestinal malignancies who have failed prior therapy.
Garrett CR; Siu LL; El-Khoueiry A; Buter J; Rocha-Lima CM; Marshall J; LoRusso P; Major P; Chemidlin J; Mokliatchouk O; Velasquez L; Hayes W; Feltquate D; Syed S; Ford S; Kollia G; Galbraith S; Nuyten DS
Br J Cancer; 2011 Jun; 105(1):44-52. PubMed ID: 21629245
[TBL] [Abstract][Full Text] [Related]
10. Phase III randomized, placebo-controlled study of cetuximab plus brivanib alaninate versus cetuximab plus placebo in patients with metastatic, chemotherapy-refractory, wild-type K-RAS colorectal carcinoma: the NCIC Clinical Trials Group and AGITG CO.20 Trial.
Siu LL; Shapiro JD; Jonker DJ; Karapetis CS; Zalcberg JR; Simes J; Couture F; Moore MJ; Price TJ; Siddiqui J; Nott LM; Charpentier D; Liauw W; Sawyer MB; Jefford M; Magoski NM; Haydon A; Walters I; Ringash J; Tu D; O'Callaghan CJ
J Clin Oncol; 2013 Jul; 31(19):2477-84. PubMed ID: 23690424
[TBL] [Abstract][Full Text] [Related]
11. Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study.
Johnson PJ; Qin S; Park JW; Poon RT; Raoul JL; Philip PA; Hsu CH; Hu TH; Heo J; Xu J; Lu L; Chao Y; Boucher E; Han KH; Paik SW; Robles-Aviña J; Kudo M; Yan L; Sobhonslidsuk A; Komov D; Decaens T; Tak WY; Jeng LB; Liu D; Ezzeddine R; Walters I; Cheng AL
J Clin Oncol; 2013 Oct; 31(28):3517-24. PubMed ID: 23980084
[TBL] [Abstract][Full Text] [Related]
12. Single-dose bioequivalence of 105-mg fenofibric acid tablets versus 145-mg fenofibrate tablets under fasting and fed conditions: a report of two phase I, open-label, single-dose, randomized, crossover clinical trials.
Godfrey AR; Digiacinto J; Davis MW
Clin Ther; 2011 Jun; 33(6):766-75. PubMed ID: 21704241
[TBL] [Abstract][Full Text] [Related]
13. Phase II, open-label study of brivanib as second-line therapy in patients with advanced hepatocellular carcinoma.
Finn RS; Kang YK; Mulcahy M; Polite BN; Lim HY; Walters I; Baudelet C; Manekas D; Park JW
Clin Cancer Res; 2012 Apr; 18(7):2090-8. PubMed ID: 22238246
[TBL] [Abstract][Full Text] [Related]
14. Effects of food intake on the pharmacokinetic properties of dalcetrapib: findings from three phase I, single-dose crossover studies in healthy volunteers.
Derks M; Kawamura H; Abt M; Meneses-Lorente G; Phelan M; Ishikawa T
Clin Ther; 2011 Jun; 33(6):754-65. PubMed ID: 21704240
[TBL] [Abstract][Full Text] [Related]
15. A study to determine the effects of food and multiple dosing on the pharmacokinetics of vorinostat given orally to patients with advanced cancer.
Rubin EH; Agrawal NG; Friedman EJ; Scott P; Mazina KE; Sun L; Du L; Ricker JL; Frankel SR; Gottesdiener KM; Wagner JA; Iwamoto M
Clin Cancer Res; 2006 Dec; 12(23):7039-45. PubMed ID: 17145826
[TBL] [Abstract][Full Text] [Related]
16. Phase II, open-label study of brivanib as first-line therapy in patients with advanced hepatocellular carcinoma.
Park JW; Finn RS; Kim JS; Karwal M; Li RK; Ismail F; Thomas M; Harris R; Baudelet C; Walters I; Raoul JL
Clin Cancer Res; 2011 Apr; 17(7):1973-83. PubMed ID: 21349999
[TBL] [Abstract][Full Text] [Related]
17. Effect of food on the pharmacokinetics of lonafarnib (SCH 66336) following single and multiple doses.
Zhu Y; Statkevich P; Cutler DL
Int J Clin Pharmacol Ther; 2007 Oct; 45(10):539-47. PubMed ID: 17966839
[TBL] [Abstract][Full Text] [Related]
18. Experimental treatment of oestrogen receptor (ER) positive breast cancer with tamoxifen and brivanib alaninate, a VEGFR-2/FGFR-1 kinase inhibitor: a potential clinical application of angiogenesis inhibitors.
Patel RR; Sengupta S; Kim HR; Klein-Szanto AJ; Pyle JR; Zhu F; Li T; Ross EA; Oseni S; Fargnoli J; Jordan VC
Eur J Cancer; 2010 Jun; 46(9):1537-53. PubMed ID: 20303261
[TBL] [Abstract][Full Text] [Related]
19. Olaparib tablet formulation: effect of food on the pharmacokinetics after oral dosing in patients with advanced solid tumours.
Plummer R; Swaisland H; Leunen K; van Herpen CM; Jerusalem G; De Grève J; Lolkema MP; Soetekouw P; Mau-Sørensen M; Nielsen D; Spicer J; Fielding A; So K; Bannister W; Molife LR
Cancer Chemother Pharmacol; 2015 Oct; 76(4):723-9. PubMed ID: 26242220
[TBL] [Abstract][Full Text] [Related]
20. Phase I safety, pharmacokinetics, and inhibition of SRC activity study of saracatinib in patients with solid tumors.
Baselga J; Cervantes A; Martinelli E; Chirivella I; Hoekman K; Hurwitz HI; Jodrell DI; Hamberg P; Casado E; Elvin P; Swaisland A; Iacona R; Tabernero J
Clin Cancer Res; 2010 Oct; 16(19):4876-83. PubMed ID: 20805299
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
